Research To Practice | Oncology Videos

View Top 200 Chart

Back to Rankings Page

Science
**Research To Practice | Oncology Videos**

Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.

Latest Episodes:

CELMoDs for Multiple Myeloma — Microlearning Activity 1 with Dr Paul G Richardson Mar 23, 2026

Show notes

Featuring perspectives from Dr Paul G Richardson, including the following topics:

Mechanism of action and pharmacology of cereblon E3 ligase modulators (0:00)
Available efficacy data (4:54)
Extramedullary disease (10:51)
Side effects and toxicity (16:58)

CME information and select publications

Immune Thrombocytopenia — Microlearning Activity 3 with Dr Hanny Al-Samkari: ASH 2025 Review Mar 21, 2026

Show notes

Featuring an interview with Dr Hanny Al-Samkari, including the following topics:

Case: A woman in her early 70s incidentally diagnosed with immune thrombocytopenia (ITP) experiences a suboptimal response to prednisone and IVIG — Bhavana (Tina) Bhatnagar, DO (0:00)
Case: A man in his early 50s with a long history of ITP undergoes splenectomy — Neil Morganstein, MD (5:06)
Case: A woman in her mid 50s with symptomatic iron-deficiency anemia who was found to have ITP has received corticosteroids, rituximab and IVIG — Jennifer Yannucci, MD (12:25)
Case: A woman in her early 30s who previously received ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine) and autologous stem cell transplant for Hodgkin lymphoma is diagnosed with ITP 5 years later that is refractory to high-dose prednisone, IVIG and rituximab, then romiplostim — Priya Rudolph, MD, PhD (18:19)

CME information and select publications

HER2-Positive Gastrointestinal Cancers — Microlearning Activity 2: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium Mar 19, 2026

Show notes

Featuring perspectives from Dr Haley Ellis, Prof Eric Van Cutsem and Dr Zev Wainberg, moderated by Dr Lionel A Kankeu Fonkoua, including the following topics:

Novel immune checkpoint inhibitors (0:00)
Gastroesophageal junction cancer (7:36)
Gastric cancer (14:52)

CME information and select publications

Breast Cancer — 5-Minute Journal Club Issue 2 with Dr Lajos Pusztai: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays Mar 18, 2026

Show notes

Featuring an interview with Dr Lajos Pusztai, including the following topics:

Circulating tumor DNA monitoring for patients with ER-positive, HER2-negative high-risk breast cancer during adjuvant endocrine therapy (0:00)
Clinical performance of a whole-genome assay for predicting disease recurrence (5:52)
Using circulating tumor DNA status to personalize CDK4/6 inhibitor therapy (12:46)
Neoadjuvant and adjuvant therapy stratified by circulating tumor DNA status (21:11)
Utility of circulating tumor DNA status in the management of metastatic breast cancer (24:55)

CME information and select publications

Desmoid Tumors — Microlearning Activity 1 with Dr Ravin Ratan Mar 16, 2026

Show notes

Featuring an interview with Dr Ravin Ratan, including the following topics:

Efficacy and safety of long-term continuous nirogacestat treatment in adults with desmoid tumors: Results from the Phase III DeFi trial (0:00)
Onset and resolution of ovarian toxicity with nirogacestat treatment for desmoid tumors: Updated safety analyses from the DeFi trial (4:37)
Subgroup analysis of the Phase II part of the RINGSIDE Phase II/III trial of varegacestat for desmoid tumors (7:39)
Surgical management of desmoid tumors; cryotherapy in the treatment of extra-abdominal desmoid tumors (10:30)

CME information and select publications

HER2-Positive Gastrointestinal Cancers — Microlearning Activity 1: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium Mar 14, 2026

Show notes

Featuring perspectives from Dr Haley Ellis, Prof Eric Van Cutsem and Dr Zev Wainberg, moderated by Dr Lionel A Kankeu Fonkoua, including the following topics:

Biliary tract cancer progressing on first-line therapy (0:00)
Gallbladder cancer (5:01)
Biliary tract cancer with multiple biomarker targets (8:52)

CME information and select publications

CD19 x CD3 BiTEs for Acute Lymphoblastic Leukemia — An Interview with Dr Bijal Shah Mar 13, 2026

Show notes

Featuring an interview with Dr Bijal Shah, including the following topics:

Advent and importance of blinatumomab in the therapeutic landscape of acute lymphoblastic leukemia (ALL) (0:00)
Similarities and differences between bispecific T-cell engagers (BiTEs) and bispecific antibodies (5:51)
Rationale underlying the development of surovatamig and MK-1045; benefits of blinatumomab for patients without detectable minimal residual disease (9:56)
Extramedullary ALL, including in the CNS (13:32)
Key principles in the development and use of surovatamig and MK-1045, including structural features and recent efficacy and safety findings (18:34)
Ongoing immunotherapy trials for ALL, including studies of BiTEs and chimeric antigen receptor T-cell therapy (25:37)
Case: A woman in her late 50s with newly diagnosed Philadelphia chromosome-positive B-cell ALL and multiple comorbidities (31:48)
Case: A woman in her early 50s with newly diagnosed B-cell ALL, a TP53 mutation and significant extramedullary disease including the CNS (41:16)
Case: A man in his early 50s with intermediate-risk B-cell ALL who receives surovatamig on a clinical trial (53:05)

CME information and select publications

CD19 x CD3 BiTEs for Acute Lymphoblastic Leukemia — An Interview with Dr Bijal Shah (Companion Faculty Lecture) Mar 12, 2026

Show notes

Featuring a slide presentation and related discussion from Dr Bijal Shah, including the following topics:

Historical approaches to managing acute lymphoblastic leukemia, their limitations and present approaches to treatment (0:00)
Mechanistic approach underlying blinatumomab; key clinical trial data and their implications (7:29)
Mechanistic approaches underlying surovatamig and MK-1045; dosing and administration strategies with various bispecific T-cell engagers (23:27)
Key clinical trial data with surovatamig; implications for practice (32:38)
Key clinical trial data with MK-1045; implications for practice (39:02)
Synthesizing and comparing data across subcutaneous blinatumomab, surovatamig and MK-1045 (42:36)

CME information and select publications

Chronic Lymphocytic Leukemia — An Interview with Prof Constantine Tam on Key Presentations from the 2025 ASH Annual Meeting Mar 11, 2026

Show notes

Featuring an interview with Prof Constantine Tam, including the following topics:

Evolving first-line treatment paradigm for patients with previously untreated chronic lymphocytic leukemia (CLL) (0:00)
Considerations for the administration of first-line venetoclax-based regimens (3:24)
Mechanism of action of sonrotoclax and observed early-phase efficacy in combination with zanubrutinib; minimal residual disease as a potential clinical trial endpoint (10:01)
Continuous versus fixed-duration first-line treatment approaches for previously untreated CLL (14:38)
Selecting between up-front acalabrutinib- and zanubrutinib-based time-limited therapy options (19:07)
Up-front treatment selection for patients with del(17p) CLL (24:01)
Stopping and restarting acalabrutinib for frail patients with previously untreated CLL (26:43)
Pirtobrutinib for treatment-naïve and relapsed/refractory CLL/small lymphocytic lymphoma: Results from the Phase III BRUIN CLL-314 and BRUIN CLL-313 trials (30:20)
Lisocabtagene maraleucel as treatment for patients with double-refractory CLL (37:00)
Perspectives on future roles of novel therapies and treatment strategies (43:11)

CME information and select publications

Chronic Lymphocytic Leukemia — An Interview with Prof Constantine Tam on Key Presentations from the 2025 ASH Annual Meeting (Companion Faculty Lecture) Mar 10, 2026

Show notes

Featuring a slide presentation and related discussion from Prof Constantine Tam, including the following topics:

Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia (CLL): Results from the randomized CLL17 trial (0:00)
Six-year follow-up data from the Phase III SEQUOIA trial of zanubrutinib for patients with treatment-naïve CLL and those with del(17p) CLL not randomly assigned (4:59)
Primary endpoint analysis of the randomized STAIR trial of time-limited acalabrutinib monotherapy for frail patients with previously untreated CLL (7:25)
Safety analyses of acalabrutinib/venetoclax (AV) or AV in combination with obinutuzumab for previously untreated CLL (10:50)
Three-year results with zanubrutinib combined with venetoclax in arm D of the Phase III SEQUOIA trial for treatment-naïve CLL (17:15)
Early-phase data with sonrotoclax combinations as front-line treatment of CLL (19:12)
Pirtobrutinib for treatment-naïve and relapsed/refractory CLL/small lymphocytic lymphoma: Results from the Phase III BRUIN CLL-314 and BRUIN CLL-313 trials (23:27)
Long-term extension (LTE1) results from the Phase III ALPINE trial of zanubrutinib versus ibrutinib in patients with relapsed/refractory CLL or small lymphocytic lymphoma (R/R CLL/SLL) (28:53)
Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with R/R CLL/SLL from the ongoing phase 1 CaDAnCe-101 study (30:35)
Real-world outcomes of lisocabtagene maraleucel in CLL (33:04)

CME information and select publications

Our TOPPODCAST Picks

Follow Us

Stay Connected

Research To Practice | Oncology Videos

Related Podcasts

Links

Stay Connected